Grant Award Details
Complete a Phase 1 clinical trial for infants with X-linked Severe Combined Immunodeficiency with lentivirus transduced autologous bone marrow stem cells and Busulphan conditioning.
Grant Application Details
- Lentiviral Gene Therapy for Infants with X-linked Severe Combined Immunodeficiency using Autologous Bone Marrow Stem Cells and Busulfan Conditioning
Therapeutic Candidate or Device
Bone marrow stem cells will be transduced with a lentiviral vector to deliver a normal copy of the gamma-chain gene to treat X-linked SCID.
x-linked severe combined immunodeficiency, a severe pediatric disorder in which children have multiple defects in their immune system.
The gene therapy will correct the patient's own bone marrow stem cells. Transplantation with these corrected cells will lead to restored production of T, B, and NK lymphocytes resulting in correction of the underlying immunoeficiency disorder. Correction of the immune cells will allow the patients to fight infections that are life-threatening without curative therapy. The patients will be spared life-long supplementation with expensive preparations of human antibody with B cell correction.
Unmet Medical Need
XSCID is a catastrophic disease of childhood. Children with matched sibling donors do well with bone marrow transplant, but most cases lack a matched sibling donor. We address this unmet need by using the patient's own bone marrow stem cells for transplantation after lentiviral transduction.
Phase I/II trial completed.
Major Proposed Activities
- Open LVXSCID-ND trial at UCSF.
- Enroll at least 6 patients from California at the UCSF performance site.
- Analyze immune reconstitution and safety in XSCID gene therapy patients.
UCSF is a major referral site for XSCID patients in California. If this gene therapy works as intended, these children will be provided curative therapy without any risk of graft-versus-host disease. Under current conditions, treatment for XSCID patients that lack matched sibling donors is very expensive, and for those that lack health insurance, a major expense for their state of residence. Lastly, this may provide commercialization opportunities for biotech companies in California.
- J Allergy Clin Immunol Pract (2021) Successful SCID gene therapy in infant with disseminated BCG. (PubMed: 32949809)
- N Engl J Med (2019) Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1. (PubMed: 30995372)
- ASGCT () Lentiviral Gene Therapy with Low Dose Busulfan for Infants with X-Linked Severe Combined Immune Deficiency (XSCID) results in the Development of a Normal and Sustained Immune System: Interim Results of an ongoing Phase I/II Clinical Study
- Blood () Interim Results from a Phase I/II Clinical Gene Therapy Study for Newly Diagnosed Infants with X-Linked Severe Combined Immunodeficiency Using a Safety-Modified Lentiviral Vector and Targeted Reduced Exposure to Busulfan